39746-15-1

Upstream product

• 17701-31-4 2,2-dimethylhexanoyl chloride 
• 756-79-6 dimethyl methane phosphonate 
• 38068-09-6 ethyl 2,2-dimethyl-hexanoate 
• 813-69-4 2,2-dimethyl-hexanoic acid methyl ester 
• 109-72-8 n-butyllithium 
• 100385-88-4 2,2-diethyl-hexanoic acid ethyl ester 
• 813-72-9 2,2-dimethylhexanoic acid 

Downstream Products

• 1013326-73-2 methyl 4-(2-{2-[(1E)-4,4-dimethyl-3-oxooct-1-enyl]-5-oxo-pyrrolidin-1-yl}ethyl)benzoate 

Relevant academic research and scientific papers

METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

Prostaglandins E and anti-ulcers containing same

The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

Copper(II) Bromide Utilization in the Synthesis of 15-Keto-PGB1 and its 16,16-Dimethyl Analog

Title compounds, monomeric intermediates of biologically active prostaglandin oligomers were synthesized using cupric bromide for introduction of a double bond into the prostanoid cyclopentane ring.

2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives

Disclosed herein are novel prostaglandin I2 (PGI2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: STR1 wherein R1, X, R2 and R3 are as defined herein.

Bicyclic lactone intermediates

Bicyclic lactone intermediates useful for preparing prostaglandin E2 -type, F2 -type, A2 -type, and B2 -type compounds with one or two methyl or ethyl substituents at the C-16 position are disclosed. These prostaglandin-type compounds are useful for the same pharmacological purposes as the corresponding prostaglandins.

Prostaglandin derivatives and process for preparing the same

Prostaglandin derivatives corresponding to the general formula: STR1 wherein R1 represents hydrogen, methyl or ethyl, R2, R3 and R4, which are the same or different, each represent hydrogen or methyl and R is selected from the groups consisting of: STR2 in which R5 represents hydrogen, methyl or ethyl, R6 represents methyl, ethyl or acetyl and R7 and R8, when they are different, each represent hydrogen or a branched- or straight-chain alkyl group having from 1 to 7 carbon atoms or R7 and R8, when they are identical, each represent hydrogen or a straight-chain alkyl group having from 1 to 3 carbon atoms with the provisos that: When both R7 and R8 represent hydrogen, R5 is methyl or ethyl, When R5 represents methyl and R2, R3, R4, R7 and R8 all represent hydrogen then R1 is ethyl, The said prostaglandin derivatives being in the form of a mixture of isomers or of an individual isomer. They are useful in the treatment of pathological states which affect the respiratory system.

8β,12α,15β-PGF2 β Compounds

This invention is a group of 8-beta, 12-alpha-PG2 (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.

11,16-Substituted prostaglandins

11-Substituted prostaglandins E1, E2 and F2α useful as cardiovascular agents and as agents for inducing labor in pregnant females and for the termination of pregnancy and a process for preparing these prostaglandins.